Status:
COMPLETED
Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp Psoriasis
Lead Sponsor:
Jinnah Postgraduate Medical Centre
Conditions:
Scalp Psoriasis
Eligibility:
All Genders
30-50 years
Phase:
NA
Brief Summary
Psoriasis is a serious, immune-driven illness that affects around 2% of the population and has a wide range of clinical manifestations 1-3 . Many patients have localized illness, and topical therapy c...
Detailed Description
Topical Corticosteroids is commonly used in situations of mild to moderate disease severity. However, long-term safety is still an issue, especially when utilizing stronger formulations,which come wit...
Eligibility Criteria
Inclusion
- Patients between 30-50 years of age, either gender presenting with scalp psoriasis as per operational definition will be included in the study.
Exclusion
- pustular psoriasis or had used phototherapy, photochemotherapy, or systemic psoriasis therapy within the last four weeks (or biologics within the last three months).
- Used topical treatment within 14 days prior to the baseline visit or who were diagnosed with skin conditions that would interfere with the interpretation of results were also excluded.
- pregnant women, women attempting to become pregnant, lactation
Key Trial Info
Start Date :
August 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2023
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT06015152
Start Date
August 1 2022
End Date
February 1 2023
Last Update
August 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
JPMC
Karachi, Sindh, Pakistan